Table 4Koliopoulos et al36: Expected False Positives, Colposcopies, CIN2-3 Cases, Cancer Cases, and Cancer Deaths Associated With Cytology and HPV Test-Based Strategies, Either Alone or in Combination*

StrategyFalse PositivesColposcopiesCIN2-3 CasesCancer CasesCancer Deaths
Cytology, q3, age 21;
Cytology and HPV, q5, age 30
401.90832.2885.136.621.08
Cytology, q5, age 21328.93693.9774.859.761.86
Cytology, q3; age 21;
Cytology and HPV, q3, age 30
600.891209.5492.363.940.53
Cytology, q3, age 21535.051090.5686.165.980.95
Cytology, q2, age 21;
Cytology and HPV, q3, age 30
834.471646.0292.332.860.36
Cytology, q2, age 21784.701563.9690.133.790.51
Cytology, q1, age 21;
Cytology and HPV, q3, age 30
1101.242141.5891.411.920.23
Cytology, q1, age 211409.782744.2588.301.370.16
*

Per 1,000 women. Time horizon is a lifetime. Age at which to begin screening is fixed at 21 years. For the combined cytology and HPV testing strategies, cytology-based screening is assumed before age 30 years, with a repeat cytology test for ASC-US results. The strategy of cytology and HPV testing begins at age 30 years. Women with normal cytology results and HPV negative results are assumed to be screened every 3 or 5 years.

From: Addendum

Cover of Screening for Cervical Cancer: A Decision Analysis for the U.S. Preventive Services Task Force
Screening for Cervical Cancer: A Decision Analysis for the U.S. Preventive Services Task Force [Internet].
Evidence Syntheses, No. 86s.
Kulasingam SL, Havrilesky L, Ghebre R, et al.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.